EGF (Epidermal Growth Factor) is a 53-amino acid polypeptide that binds to the epidermal growth factor receptor (EGFR) on cell surfaces, triggering signaling cascades that promote cell proliferation, differentiation, and survival. Discovered by Stanley Cohen in 1962 -- work for which he received the Nobel Prize in Physiology or Medicine in 1986 -- EGF is one of the most extensively studied growth factors in biology.

Overview

EGF was the first growth factor to be isolated and characterized, identified from mouse submaxillary gland extracts by Stanley Cohen at Vanderbilt University. Human EGF is produced by platelets, macrophages, and monocytes and is found in saliva, urine, milk, and plasma. Endogenous EGF levels decline with age, contributing to slower wound healing and reduced epidermal turnover. Recombinant human EGF (rhEGF) has been developed for therapeutic use, including FDA-cleared wound care products for diabetic foot ulcers and burn injuries. In cosmetics, biosynthetic EGF is incorporated into serums and creams to promote skin renewal and reduce visible signs of aging.

Mechanism of Action

EGF binds to the extracellular domain of the EGF receptor (EGFR/ErbB1/HER1), a transmembrane receptor tyrosine kinase. Ligand binding induces receptor dimerization and autophosphorylation, activating three major downstream signaling cascades: the RAS-RAF-MEK-ERK (MAPK) pathway driving cell proliferation, the PI3K-AKT pathway promoting cell survival, and the JAK-STAT pathway regulating gene transcription. These pathways collectively stimulate keratinocyte and fibroblast proliferation, accelerate epithelial migration across wound beds, increase production of extracellular matrix components, and suppress apoptosis in damaged tissue Carpenter & Cohen (1990)45534-0). The three intramolecular disulfide bonds maintain the structural integrity required for receptor binding affinity.

Reconstitution Calculator

Research

Safety Profile

Topical EGF has a well-established safety profile in cosmetic and wound care applications. No significant systemic absorption occurs through intact skin, and local adverse effects are rare. However, EGF's role in stimulating cell proliferation has raised theoretical concerns regarding its use in individuals with a history of or predisposition to cancer. EGFR is overexpressed in many carcinomas, and chronic stimulation of this pathway could theoretically promote tumor growth. Regulatory bodies in several countries have debated the inclusion of EGF in cosmetics, and South Korea's MFDS has issued guidelines on its use. Current evidence does not demonstrate carcinogenic risk from topical cosmetic concentrations, but the debate has led some brands to avoid EGF in favor of alternative growth factors. Injectable formulations require clinical oversight due to the more direct mitogenic effects at higher local concentrations.

Post-Procedure Recovery

EGF-containing formulations are increasingly used following dermatological procedures including laser resurfacing, microneedling, chemical peels, and dermabrasion. Applied immediately after treatment, EGF accelerates re-epithelialization of the treated surface, reducing erythema duration and minimizing infection risk during the vulnerable healing window. Split-face studies have demonstrated faster recovery on EGF-treated sides compared to standard post-procedure care, with reduced crusting and earlier return to normal appearance Hou et al. (2020).

Cosmetic Controversy

EGF's mechanism of action -- promoting cell proliferation through EGFR activation -- has generated ongoing debate in the cosmetics industry. Since EGFR is overexpressed in many epithelial cancers and anti-EGFR therapies (cetuximab, erlotinib) are established cancer treatments, some researchers and regulatory bodies have questioned whether topical EGF application could theoretically promote or accelerate skin cancer development. Proponents counter that topical concentrations are orders of magnitude below those needed for systemic EGFR activation, that the stratum corneum limits penetration, and that decades of topical EGF use have not produced epidemiological signals of increased cancer risk. The European Scientific Committee on Consumer Safety (SCCS) has reviewed EGF and similar growth factors without issuing a ban, though several Asian regulatory bodies have imposed concentration limits.

Pharmacokinetic Profile